Organon & (US:OGN) Prnewswire·2025-06-02 19:59Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for allegedly misrepresenting its capital allocation priorities and significantly reducing its quarterly dividend [1][6]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of New Jersey [1]. - Investors who acquired Organon shares during the class period (October 31, 2024 – April 30, 2025) are encouraged to contact the law firm before the lead plaintiff motion deadline on July 22, 2025 [1][3][6]. Group 2: Allegations Against Organon - Organon is accused of concealing material information regarding its capital allocation priorities, particularly about its quarterly dividend [6]. - The company allegedly misrepresented its commitment to dividends while internally prioritizing debt reduction [6]. - Following the acquisition of Dermavant Sciences Ltd., Organon reduced its quarterly dividend by over 70% [6].